Differential body composition effects of protease inhibitors recommended for initial treatment of HIV infection: A randomized clinical trial

Clinical Infectious Diseases

Volumn 60, Issue 5, 2015, Pages 811-820

  Martinez, Esteban ^a   González Cordón, Ana ^a,m   Ferrer, E ^b   Domingo, P ^r   Negredo, E ⁿ   Gutierrez, Felix ^d   Portilla, J ^e   Curran, A ^f   Podzamczer, D ^b   Ribera, E ^f   Murillas, Javier ^g   Bernardino, J I ^h   Santos, I ⁱ   Carton, Jose A ^j,l   Peraire, J ^k   Pich, J ^t   Deulofeu, Ramon ^a   Perez, Ignacio ^a   Gatell, J M ^m   Arnaiz, Juan A ^u   Beleta, Helena ^u   Garcia, David ^u   Pejenaute, Andrea ^u   Ramos, Nuria ^u   Arcaina, P ^e   Giner, L ^e   Moya, S ^e   Pampliega, M ^e   Barrera, G ^b   Rozas, N ^b   Saumoy, M ^b   Asensi, V ^l   Perez I ^m   Martinez E ^m   Masia M ^d   Padilla, S ^d   Ramos, J R ^d   Robledano, C ^d   Gutierrez F ^d   Puig, J ⁿ   Arribas, J R ^h   Castro, J M ^h   Sanz, J ⁱ   Cairo M ^o   Velli, P ^o   Dalmau, D ^o   Lamas, A ^p   Marti Belda P ^p   Dronda, F ^p   Blanco, J R ^q   Gutierrez, M ^r   Mateo, M G ^r   Losada, E ^s   Prieto, A ^s   Antela, A ^s   Aguilar, A ^k   Vargas, M ^k   Vilades C ^k   Vidal, F ^k   Crespo, M ^f   more..

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^f HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^g HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^h HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

ⁱ HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^j UNIVERSITY OF OVIEDO   (Spain)

^k HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^l HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^m HOSPITAL CLÍNIC   (Spain)

ⁿ IrsiCaixa Foundation   (Spain)

^o HOSPITAL MÚTUA DE TERRASSA   (Spain)

^p HOSPITAL RAMÓN Y CAJAL   (Spain)

^q HOSPITAL SAN PEDRO   (Spain)

^r HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^s University Hospital of Santiago de Compostela   (Spain)

^t CTU Barcelona   (Spain)

^u Hospital de Sant Pau ^*

more..

Author keywords

Antiretroviral therapy; Body composition; HIV protease inhibitors; Plasma lipids

Indexed keywords

ATAZANAVIR PLUS RITONAVIR; DARUNAVIR PLUS RITONAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR;

ABDOMINAL SUBCUTANEOUS FAT; ADULT; ARTICLE; BODY COMPOSITION; BODY FAT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS FAT; TREATMENT FAILURE; TRIACYLGLYCEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG EFFECTS; HIV INFECTIONS; MIDDLE AGED; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; BODY COMPOSITION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84935501553     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu898     Document Type: Article

References (40)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. (Last updated: 5/1/2014). Available at: http://aidsinfo.nih.gov/ContentFiles/Adultand AdolescentGL.pdf. Accessed 24 October 2014.
2. European AIDS Clinical Society Guidelines. Version 7.2, June 2014. Available at: http://www.eacsociety.org/Portals/0/140601-EACS% 20EN7.02.pdf. Accessed 24 October 2014.
3. Panel de expertos de GeSIDA y Plan Nacional sobre el Sida. Documento de consenso de GeSIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (Actualización enero 2014). Available at: http:// www.gesida-seimc.org/contenidos/guiasclinicas/2014/gesida-guiascli nicas-2014-tar.pdf. Accessed 24 October 2014.
4. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008; 372:646-55.
5. Ortiz R, Dejesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS 2008; 22:1389-97.
6. Samaras K, Richardson R, Carr A. Postprandial lipid effects of low-dose ritonavir vs. raltegravir in HIV-uninfected adults. AIDS 2010; 24: 1727-31.
7. Taylor SA, Lee GA, Pao VY, et al. Boosting-dose ritonavir does not alter peripheral insulin sensitivity in healthy HIV-seronegative volunteers. J Acquir Immune Defic Syndr 2010; 55:361-4.
8. Tomaka F, Lefebvre E, Sekar V, et al. Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers. HIV Med 2009; 10:318-27.
9. Boffito M, Jackson A, Amara A, et al. Pharmacokinetics of once-daily darunavir-ritonavir and atazanavir-ritonavir over 72 hours following drug cessation. Antimicrob Agents Chemother 2011; 55:4218-23.
10. Puls R, Srasuebkul P, Petoumenos K, Emery S, Cooper DA. Anthropometric and metabolic outcomes in a 48-week randomized, open-label study of three different combination antiretroviral regimens as initial therapy for HIV infection. Antivir Ther 2009; 14(suppl 2):A8.
11. McComsey GA, Kitch D, Sax PE, et al. Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s. Clin Infect Dis 2011; 53:185-96.
12. Moyle GJ, Hardy H, Farajallah A, DeGrosky M, McGrath D. Comparison of body composition changes between ataznavir/ritonavir and lopinavir/ritonavir each in combination with tenofovir/emtricitabine in antiretroviral-naïve patients with HIV-1 infection. Clin Drug Investig 2014; 34:287-96.
13. Bentué-Ferrer D, Arvieux C, Tribut O, Ruffault A, Bellissant E. Clinical pharmacology, efficacy and safety of atazanavir: a review. Expert Opin Drug Metab Toxicol 2009; 5:1455-68.
14. Dekker D, Dorresteijn MJ, Pijnenburg M, et al. The bilirubin-increasing drug atazanavir improves endothelial function in patients with type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 2011; 31:458-63.
15. Aberg JA, Tebas P, Overton ET, et al. Metabolic effects of darunavir/ ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks. AIDS Res Hum Retrovir 2012; 28: 1184-95.
16. Martinez E, Gonzalez-Cordon A, Ferrer E, et al. Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir. HIV Med 2014; 15:330-8.
17. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41:1-19.
18. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18:499-502.
19. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150:604-12.
20. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-9.
21. Fukunaga K, Yoshida M, Nakazono N. A simple highly sensitive and reproducible quantification method for plasma malondialdehyde by high performance liquid chromatography. Biomed Chromatography 1998; 12:300-3.
22. Nolan D, Hammond E, James I, McKinnon E, Mallal S. Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level. Antiv Ther 2003; 8: 617-26.
23. Division of AIDS (DAIDS). Table for Grading the Severity of Adult and Pediatric Adverse Events. Version 1.0. December 2004 (Clarification dated August 2009). Available at: http://rcc.tech-res.com/safetyandphar macovigilance. Accessed 24 October 2014.
24. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 Explanation and elaboration: updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol 2010; 63:e1-37.
25. Lennox JL, Landovitz RJ, Ribaudo HJ, et al. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naïve volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med 2014; 161:461-71.
26. Kuritzkes DR. Drug resistance in HIV-1. Curr Opin Virol 2011; 1: 582-9.
27. Daar ES, Tierney C, Fischl MA, et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med 2011; 154:445-56.
28. DeJesus E, Rockstroh JK, Henry K, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet 2012; 379:2429-38.
29. McDonald C, Uy J, Hu W, et al. Clinical significance of hyperbilirubinemia among HIV-1-infected patients treated with ataznavir/ritonavir through 96 weeks in the CASTLE study. AIDS Patient Care STDS 2012; 26:259-64.
30. Saumoy M, Ordoñez-Llanos J, Martinez E, et al. Atherogenic properties of lipoproteins in HIV patients starting atazanavir/ritonavir or darunavir/ ritonavir: metabolic ATADAR sub-study. J Antimicrob Chemother 2014 (accepted for publication on October 24 2014).
31. Lin N, Fu J, Koonen DP, Kuivenhoven JA, Snieder H, Hofker MH. Are hypertriglyceridemia and low HDL causal factors in the development of insulin resistance? Atherosclerosis 2014; 233:130-8.
32. Jones CY, Hogan JW, Snyder B, et al. Overweight and human immunodeficiency virus (HIV) progression in women: associations HIV disease progression and changes in body mass index in women in the HIV epidemiology research study cohort. Clin Infect Dis 2003; 37(suppl 2): S69-80.
33. Hammond E, McKinnon E, Nolan D. Human immunodeficiency virus treatment-induced adipose tissue pathology and lipoatrophy: prevalence and metabolic consequences. Clin Infect Dis 2010; 51:591-9.
34. McLaughlin T, Lamendola C, Liu A, Abbasi F. Preferential fat deposition in subcutaneous versus visceral depots is associated with insulin sensitivity. J Clin Endocrinol Metab 2011; 96:E1756-60.
35. Guaraldi G, Stentarelli C, Zona S, Santoro A. HIV-associated lipodystrophy: impact of antiretroviral therapy. Drugs 2013; 73:1431-50.
36. Patel P, Abate N. Body fat distribution and insulin resistance. Nutrients 2013; 5:2019-7.
37. Porter SA, Massaro JM, Hoffmann U, Vasan RS, O'Donnel CJ, Fox CS. Abdominal subcutaneous adipose tissue: a protective fat depot. Diab Care 2009; 32:1068-75.
38. Ferrer E, del Rio L, Martinez E, et al. Impact of switching from lopinavir/ ritonavir to atazanavir/ritonavir on body fat redistribution in virologically suppressed HIV-infected adults. AIDS Res Hum Retrovir 2011; 27:1061-5.
39. Moyle G, Andrade-Villanueva J, Girard PM, et al. A randomized comparative 96-week trial of boosted atazanavir versus continued boosted protease inhibitor in HIV-1 patients with abdominal adiposity. Antivir Ther 2012; 17:689-700.
40. Capel E, Auclair M, Caron-Debarle M, Capeau J. Effects of ritonavirboosted darunavir, atazanavir and lopinavir on adipose functions and insulin sensitivity in murine and human adipocytes. Antivir Ther 2012; 17:549-56.